NGEN NervGen Pharma Corp.
Price Chart
Executive Summary
NervGen Pharma reported Q1 2026 net loss of $1.7M ($0.09 diluted EPS) vs consensus $-0.07, a 28.6% miss on the Street-quoted metric. The company highlighted FDA alignment on its RESTORE registrational study for NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026. Cash and investments of $16.6M provide runway into late 2026, but the EPS miss and lack of revenue reinforce the pre-commercial, high-burn clinical-stage profile.
Actionable Insight
The EPS miss and rising cash burn without revenue create near-term pressure, but the FDA-aligned RESTORE study initiation in mid-2026 is the primary catalyst. Monitor Q2 2026 for CONNECT SCI biomechanical gait analysis results and any financing announcements to extend runway beyond late 2026.
Key Facts
- Q1 2026 diluted EPS of $-0.09 vs consensus $-0.07 (28.6% miss on Street-convention EPS)
- Net loss of $1.7M improved from $3.9M in Q1 2025, driven by $5.7M non-cash unrealized gain on warrant derivative
- Cash and investments of $16.6M as of March 31, 2026
- FDA End-of-Phase 2 meeting completed; RESTORE registrational study on track for mid-2026 initiation
- Biomechanical gait analysis results from CONNECT SCI study expected in Q2 2026
- R&D expenses rose to $4.9M from $3.1M YoY, reflecting preparation for RESTORE study
- Three senior leadership appointments to support late-stage development and Nasdaq listing
Financial Impact
EPS miss of 28.6% on Street-convention diluted EPS; cash burn rate ~$7.6M/quarter (R&D + G&A) implies ~6-7 quarters of runway
Risk Factors
- Cash runway of $16.6M may require dilutive financing before RESTORE data readout
- Clinical-stage biotech with no approved products or revenue; binary risk on RESTORE study outcomes
- EPS miss of 28.6% on Street-convention metric signals operational underperformance vs expectations
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296505 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
11d ago
|
6-K
| $2.00 $1.91 | ▲ +4.50% | ▲ +3.78% | $1.92 (+4.00%) |
|
May 27, 2026
17d ago
|
EFFECT
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.07% | $1.92 (−7.25%) |
|
May 26, 2026
17d ago
|
6-K
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.06% | $1.92 (−7.25%) |
|
May 22, 2026
21d ago
|
6-K
| $2.13 $2.07 | ▲ +2.82% | ▲ +2.83% | $1.92 (+9.86%) |
|
May 22, 2026
22d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 21, 2026
22d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 18, 2026
25d ago
|
6-K
| $3.56 $3.74 | ▲ +5.06% | ▲ +4.02% | $1.92 (−46.07%) |
|
May 18, 2026
26d ago
|
Press Release
| $3.64 $3.56 | ▲ +2.20% | ▲ +1.55% | $1.92 (+47.25%) |
|
Apr 27, 2026
6w ago
|
6-K
| $3.88 $3.75 | ▼ −3.41% | ▼ −3.40% | $1.92 (−50.52%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $3.77 $4.36 | ▲ +15.65% | ▲ +14.90% | $1.92 (−49.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access